Last week, a legislator from Texas introduced a measure that would require the state to look into the therapeutic possibilities that ketamine, MDMA and psilocybin possess, which could help treat various mental health disorders.The bill, introduced by Rep. Alex Dominguez, would order that the Department of State Health in collaboration with the Texas Medical Board Services carry out the study and present their findings by Dec. 1, 2022.

The bill, HB 1802, states that the researchers should assess and establish whether alternative therapies are successful in treating various mental health conditions such as chronic migraines and pain, bipolar disorder, post-traumatic stress disorder, anxiety and depression. Additionally, the bill emphasizes the need for the study to compare the effectiveness of alternative therapies with the effectiveness of the treatments that are presently being used to treat mental health and other medical conditions.

This legislation comes at a time when the debate on drug policy reform across the country is extending beyond cannabis, this being the latest example of state legislators taking alternative therapies and psychedelics more seriously in the midst of a nationwide movement to decriminalize entheogenic substances.

Earlier in November, Oregonians passed historic measures to decriminalize drugs on the whole and another that legalized the use of psilocybin for therapeutic purposes. For the 2021 session, legislators from Washington, California, Virginia, Connecticut, New York, Hawaii and Florida are also looking into various drug and psychedelics reform bills. Additionally, a Republican lawmaker recently introduced a bill that would decriminalize psilocybin in Iowa.

With regard to Texas though, many are skeptical that psychedelics reform will be approved, especially considering the state’s resistance to cannabis legalization in the past. In spite of this, there are some indications that legislators may be more open to debating during this session.

Furthermore, more than a dozen different cannabis legislations were prefiled for this session, including proposals that would decriminalize small-scale cannabis possession and legalize the use of high-THC marijuana for medical use as well as adult-use marijuana.

Last month, House Speaker Dade Phelan stated that the chamber would look over the reform measures and review them again. In addition to this, Lt. Gov. Dan Patrick, who oversees the state Senate, proposed that he may entertain the debate on further medical marijuana reform, adding that despite this, he is still opposed to extensive legalization. He explained that broadly legalizing cannabis would only create a front for people to easily obtain slips from doctors, which allowed them to purchase marijuana for recreational use.

Meanwhile, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) is poised to be a leader of the companies seeking to develop and commercialize psychedelic medicines as well as functional mushroom products due to its cannabis extraction experience.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

The post New Texas Legislation Will Allow State to Study MDMA, Psilocybin as Potential Treatments for Depression and PTSD appeared first on PsychedelicNewsWire (PNW).

Previous articleAlgernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Next articleDifferentiating DMT and Near-Death Experiences